GlassScriptPhysician profile
Julie C Springer
NPI 1790084267
$5,497.10
in general payments reported to CMS, 2019-2025
31 companies · $662 in 2025
The $662 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $453 · 2021: $1,043 · 2022: $988 · 2023: $906 · 2024: $927 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,396 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,396.25 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.73 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Amgen INC. | $519.27 | 2019-2025 | Evenity, Prolia, Prolia |
| Mayne Pharma Commercial LLC | $408.04 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $397.81 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $323.83 | 2019-2022 | |
| Shield Therapeutics INC | $307.95 | 2023-2025 | Accrufer |
| Hologic Sales and Service, LLC | $301.82 | 2019-2025 | Aptima, Myosure Tissue Removal Device, Acessa Provu System |
| Astellas Pharma US INC | $266.24 | 2021-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $252.37 | 2019-2024 | Slynd |
| Aspira Women'S Health INC | $237.59 | 2022 | |
| Pfizer INC. | $193.85 | 2019-2025 | |
| Myovant Sciences INC. | $187.01 | 2021-2022 | |
| Coopersurgical, INC. | $159.01 | 2019-2025 | Paragard T 380a, Wallach Cryosurgical Equipment |
| Organon LLC | $156.08 | 2022-2025 | Nexplanon |
| Lilly USA, LLC | $137.05 | 2021-2025 | Zepbound, Mounjaro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $131.59 | 2021-2024 | Twirla |
| Merck Sharp & Dohme LLC | $102.50 | 2019-2024 | Gardasil 9, Gardasil |
| Mylan Pharmaceuticals INC. | $87.80 | 2019-2021 | |
| Avion Pharmaceuticals | $85.67 | 2020-2023 | Balcoltra |
| Biogen, INC. | $85.51 | 2025 | Zurzuvae |
| Millicent US INC | $73.92 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Amag Pharmaceuticals, INC. | $59.52 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.98 | 2020-2025 | |
| Boston Scientific Corporation | $46.16 | 2021 | |
| Exact Sciences Corporation | $38.64 | 2024-2025 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $24.58 | 2023 | Bd Onclarity |
| Medicem INC. | $20.04 | 2020 | |
| Allergan, INC. | $14.37 | 2019 | |
| Dysis Medical, INC. | $13.03 | 2019 | |
| Lupin INC. | $12.09 | 2020 | |
| Acessa Health INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.